Momelotinib

Phase 3

GSK plc (GSK)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q2 '27

GSKPhase 2$100.5B

Momelotinib Phase 2 Est. Readout

Momelotinib• Primary Myelofibrosis80

Q2 2027~QEstimated

CT.gov

00%

Development History

Oct '26

GSKPhase 2$100.5B

Momelotinib Phase 2 Est. Readout

Momelotinib• Primary Myelofibrosis56

Oct 2026~Estimated

CT.gov

00%

Competitive Landscape

0 competitors in Primary Myelofibrosis

View Full Landscape

Drug Information

Target Indication

Primary Myelofibrosis

Clinical Trial

NCT01236638

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA1/25/2024

Omjjara

Omjjara is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis and who are Janus Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.

Orphan

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

GSK

GSK plc

Pharmaceutical Preparations•Europe•NYSE

Related Pipeline

Combined Hepatitis A and B vaccinePhase 3

Hepatitis B

GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix)Phase 3